{"nctId":"NCT02914561","briefTitle":"Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease","startDateStruct":{"date":"2016-10-31","type":"ACTUAL"},"conditions":["Crohn's Disease"],"count":1372,"armGroups":[{"label":"Cohort A: Filgotinib 200 (mg) (Induction Study)","type":"EXPERIMENTAL","interventionNames":["Drug: Filgotinib","Other: Placebo"]},{"label":"Cohort A: Filgotinib 100 mg (Induction Study)","type":"EXPERIMENTAL","interventionNames":["Drug: Filgotinib","Other: Placebo"]},{"label":"Cohort A: Placebo (Induction Study)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Filgotinib","Other: Placebo"]},{"label":"Cohort B: Filgotinib 200 mg (Induction Study)","type":"EXPERIMENTAL","interventionNames":["Drug: Filgotinib","Other: Placebo"]},{"label":"Cohort B: Filgotinib 100 mg (Induction Study)","type":"EXPERIMENTAL","interventionNames":["Drug: Filgotinib","Other: Placebo"]},{"label":"Cohort B: Placebo (Induction Study)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Filgotinib","Other: Placebo"]},{"label":"Filgotinib 200 mg to Filgotinib 200 mg (Maintenance Study)","type":"EXPERIMENTAL","interventionNames":["Drug: Filgotinib"]},{"label":"Filgotinib 200 mg to Placebo (Maintenance Study)","type":"EXPERIMENTAL","interventionNames":["Drug: Filgotinib","Other: Placebo"]},{"label":"Filgotinib 100 mg to Filgotinib 100 mg (Maintenance Study)","type":"EXPERIMENTAL","interventionNames":["Drug: Filgotinib"]},{"label":"Filgotinib 100 mg to Placebo (Maintenance Study)","type":"EXPERIMENTAL","interventionNames":["Drug: Filgotinib","Other: Placebo"]},{"label":"Placebo to Placebo (Maintenance Study)","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Filgotinib","otherNames":["GS-6034","GLPG0634"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Documented diagnosis of CD with a minimum disease duration of 3 months with involvement of the ileum and/or colon at a minimum, as determined by histopathology and endoscopic assessment\n* Moderately to severely active CD\n* Cohort A (Biologic Naïve): Previously demonstrated an inadequate clinical response, loss of response to, or intolerance to at least 1 of the following agents (depending on current country treatment recommendations/guidelines): corticosteroids and immunomodulators\n* Cohort A (Biologic Experienced): Previously demonstrated an inadequate clinical response, loss of response to, or intolerance to at least 1 of the following agents (depending on current country treatment recommendations/guidelines) or discontinuation of use of at least one of the following agents for reasons other than inadequate clinical response, loss of response or intolerance: tumor necrosis factor alpha (TNFa) antagonists, vedolizumab, and ustekinumab\n* Cohort B (Biologic Experienced): Previously demonstrated an inadequate clinical response, loss of response to, or intolerance to at least 1 of the following agents (depending on current country treatment recommendations/guidelines): TNFa antagonists, vedolizumab, and ustekinumab\n\nKey Exclusion Criteria:\n\n* Current complications of CD such as symptomatic strictures, severe rectal/anal stenosis, fistulae other than perianal fistulae, short bowel syndrome, etc.\n* Presence of ulcerative colitis, indeterminate colitis, ischemic colitis, fulminant colitis, or toxic mega-colon\n* Active tuberculosis (TB) or history of latent TB that has not been treated\n* Use of any prohibited concomitant medications as described in the study protocol\n\nNOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Induction Study: Percentage of Participants Who Achieved Clinical Remission by Crohn's Disease Activity Index (CDAI) at Week 10","description":"The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.\n\nClinical remission was defined as a CDAI of \\< 150 points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"25.7","spread":null},{"groupId":"OG002","value":"19.8","spread":null},{"groupId":"OG003","value":"26.7","spread":null},{"groupId":"OG004","value":"16.7","spread":null},{"groupId":"OG005","value":"14.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Induction Study: Percentage of Participants Who Achieved Endoscopic Response at Week 10","description":"The Simple Endoscopic Score for Crohn's Disease (SES-CD) assessed the degree of inflammation on the basis of 4 components: size of ulcers, ulcerated surface, affected surface, and presence of narrowing. Each of these components was scored on a scale of 0 to 3 (worst). In the SES-CD, each of these 4 components are assessed in the five segments: ileum, right colon, transverse colon, left colon, and rectum. The SES-CD was the sum of the individual scores of each of the components across the five segments. The range of SES-CD scores was 0 - 12 for each segment, and 0 - 60 for the overall SES-CD score, with larger scores indicating greater severity of disease. Endoscopic response was defined as ≥ 50% reduction from baseline in total SES-CD score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":null},{"groupId":"OG001","value":"20.8","spread":null},{"groupId":"OG002","value":"18.1","spread":null},{"groupId":"OG003","value":"11.9","spread":null},{"groupId":"OG004","value":"13.6","spread":null},{"groupId":"OG005","value":"11.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Maintenance Study: Percentage of Participants Who Achieved Clinical Remission by CDAI at Week 58","description":"The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.\n\nClinical remission was defined as a CDAI of \\< 150 points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"23.5","spread":null},{"groupId":"OG002","value":"28.3","spread":null},{"groupId":"OG003","value":"22.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Maintenance Study: Percentage of Participants Who Achieved Endoscopic Response at Week 58","description":"The SES-CD assessed the degree of inflammation on the basis of 4 components: size of ulcers, ulcerated surface, affected surface, and presence of narrowing. Each of these components was scored on a scale of 0 to 3 (worst). In the SES-CD, each of these 4 components are assessed in the five segments: ileum, right colon, transverse colon, left colon, and rectum. The SES-CD was the sum of the individual scores of each of the components across the five segments. The range of SES-CD scores was 0 - 12 for each segment, and 0 - 60 for the overall SES-CD score, with larger scores indicating greater severity of disease. Endoscopic response was defined as ≥ 50% reduction from baseline in total SES-CD score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4","spread":null},{"groupId":"OG001","value":"18.4","spread":null},{"groupId":"OG002","value":"9.4","spread":null},{"groupId":"OG003","value":"13.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Study: Percentage of Participants Who Achieved Clinical Remission by PRO2 at Week 10","description":"The PRO2 was a composite score based on 2 components of the CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3) assessed for 7 days. Clinical Remission was defined as the average daily stool score ≤3 points AND average daily abdominal pain score ≤1 point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"30.6","spread":null},{"groupId":"OG002","value":"25.7","spread":null},{"groupId":"OG003","value":"29.7","spread":null},{"groupId":"OG004","value":"18.9","spread":null},{"groupId":"OG005","value":"17.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Study: Percentage of Participants Who Achieved Clinical Response by CDAI at Week 10","description":"The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.\n\nClinical response was defined as reduction in CDAI score from Induction baseline by at least 100 points or CDAI score \\< 150 points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.3","spread":null},{"groupId":"OG001","value":"46.1","spread":null},{"groupId":"OG002","value":"39.7","spread":null},{"groupId":"OG003","value":"38.6","spread":null},{"groupId":"OG004","value":"35.5","spread":null},{"groupId":"OG005","value":"27.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Study: Percentage of Participants Who Achieved Clinical Remission by PRO2 at Week 58","description":"The PRO2 was a composite score based on 2 components of the CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3) assessed for 7 days. Clinical Remission was defined as the average daily stool score ≤3 points AND average daily abdominal pain score ≤1 point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null},{"groupId":"OG001","value":"29.6","spread":null},{"groupId":"OG002","value":"26.4","spread":null},{"groupId":"OG003","value":"24.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Study: Percentage of Participants Who Achieved Clinical Response by CDAI at Week 58","description":"The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.\n\nClinical response was defined as reduction in CDAI score from Induction baseline by at least 100 points or CDAI score \\< 150 points.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null},{"groupId":"OG001","value":"33.7","spread":null},{"groupId":"OG002","value":"34.0","spread":null},{"groupId":"OG003","value":"30.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Study: Percentage of Participants Who Achieved Sustained Clinical Remission by CDAI at Both Weeks 10 and 58","description":"The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.\n\nSustained Clinical Remission by CDAI: CDAI \\<150 combined at both Week 10 and Week 58.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.4","spread":null},{"groupId":"OG001","value":"19.4","spread":null},{"groupId":"OG002","value":"22.6","spread":null},{"groupId":"OG003","value":"20.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Study: Percentage of Participants Who Achieved 6 Month Corticosteroid-Free Remission by CDAI at Week 58","description":"The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The subscores of abdominal pain (0-3), general well-being (0-4), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.\n\n6-Month Corticosteroid-Free Clinical remission by CDAI: CDAI \\<150 with no corticosteroid use for indication of Crohn's disease for at least 6 months prior to Week 58.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.0","spread":null},{"groupId":"OG001","value":"4.9","spread":null},{"groupId":"OG002","value":"20.0","spread":null},{"groupId":"OG003","value":"12.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Study: Percentage of Participants Who Achieved Sustained Clinical Remission by PRO2 at Both Weeks 10 and 58","description":"The PRO2 was a composite score based on 2 components of the CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3) assessed for 7 days.\n\nSustained Clinical Remission by PRO2: liquid or very soft stool ≤3 and abdominal pain ≤1 combined at both Week 10 and Week 58.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","spread":null},{"groupId":"OG001","value":"25.5","spread":null},{"groupId":"OG002","value":"20.8","spread":null},{"groupId":"OG003","value":"24.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Study: Percentage of Participants Who Achieved 6 Month Corticosteroid-Free Remission by PRO2 at Week 58","description":"The PRO2 was a composite score based on 2 components of the CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3) assessed for 7 days.\n\n6-month Corticosteroid-Free Clinical Remission by PRO2: liquid or very soft stool ≤3 and abdominal pain ≤1 with no corticosteroid use for at least 6 months prior to Week 58.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","spread":null},{"groupId":"OG001","value":"7.3","spread":null},{"groupId":"OG002","value":"20.0","spread":null},{"groupId":"OG003","value":"12.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Study:Pharmacokinetic Plasma Concentrations of Filgotinib at Week 4","description":"Plasma concentrations of filgotinib \\[nanogram/milliliters (ng/mL)\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1170","spread":"1270"},{"groupId":"OG001","value":"611","spread":"634"},{"groupId":"OG002","value":"1140","spread":"1070"},{"groupId":"OG003","value":"604","spread":"634"}]}]}]},{"type":"SECONDARY","title":"Induction Study: Pharmacokinetic Plasma Concentrations of Filgotinib at Week 10","description":"Plasma concentrations of filgotinib (ng/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.8","spread":"180"},{"groupId":"OG001","value":"21.3","spread":"79.5"},{"groupId":"OG002","value":"47.9","spread":"215"},{"groupId":"OG003","value":"40.8","spread":"139"}]}]}]},{"type":"SECONDARY","title":"Maintenance Study: Pharmacokinetic Plasma Concentrations of Filgotinib at Week 26","description":"Plasma concentrations of filgotinib (ng/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"284","spread":"623"},{"groupId":"OG001","value":"58.5","spread":"150"}]}]}]},{"type":"SECONDARY","title":"Maintenance Study: Pharmacokinetic Plasma Concentrations of Filgotinib at Week 58","description":"Plasma concentrations of filgotinib (ng/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":"238"},{"groupId":"OG001","value":"16.9","spread":"55.5"}]}]}]},{"type":"SECONDARY","title":"Induction Study: Pharmacokinetic Plasma Concentrations of Filgotinib's Metabolite GS-829845 at Week 4","description":"Plasma concentrations of GS-829845 (ng/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3100","spread":"1530"},{"groupId":"OG001","value":"1800","spread":"936"},{"groupId":"OG002","value":"3140","spread":"1450"},{"groupId":"OG003","value":"1870","spread":"776"}]}]}]},{"type":"SECONDARY","title":"Induction Study: Pharmacokinetic Plasma Concentrations of Filgotinib's Metabolite GS-829845 at Week 10","description":"Plasma concentrations of GS-829845 (ng/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2550","spread":"1390"},{"groupId":"OG001","value":"1290","spread":"801"},{"groupId":"OG002","value":"2640","spread":"1470"},{"groupId":"OG003","value":"1480","spread":"917"}]}]}]},{"type":"SECONDARY","title":"Maintenance Study: Pharmacokinetic Plasma Concentrations of Filgotinib's Metabolite GS-829845 at Week 26","description":"Plasma concentrations of GS-829845 (ng/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3090","spread":"1500"},{"groupId":"OG001","value":"1460","spread":"814"}]}]}]},{"type":"SECONDARY","title":"Maintenance Study: Pharmacokinetic Plasma Concentrations of Filgotinib's Metabolite GS-829845 at Week 58","description":"Plasma concentrations of GS-829845 (ng/mL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2430","spread":"1430"},{"groupId":"OG001","value":"1220","spread":"551"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":222},"commonTop":["Crohn's disease","Headache","Abdominal pain","Nausea","Nasopharyngitis"]}}}